To catch a buffalo: field immobilisation of Asian swamp buffalo using etorphine and xylazine

OBJECTIVE: To demonstrate the efficacy of a mixture of etorphine and xylazine to safely immobilise wild buffalo (Bubalus bubalis) in the field. METHODS: Body mass was estimated (to calculate mass-specific dosages) by deriving a predictive relationship between morphometric measurements (body length, height) and mass based on a dataset collected in Vietnam, because the study animals could not be weighed in the field. RESULTS: Mass-specific dosages varied between 0.02 and 0.03 mg/kg for etorphine and between 0.14 and 0.22 mg/kg for xyalazine; induction times varied between 10 and 33 min, mean recumbency time was 68 min, and the mean time to standing was 10 min (range: 10-17 min). CONCLUSIONS: The mixture of ethorphine and xylazine was effective for immobilisation of this species and appeared to have a relatively large safety margin, based on the mass-specific dosages used. The allometric relationships described here should prove useful for those working with wild swamp buffalo.     

Enteritis associated with Yersinia pseudotuberculosis infection in a buffalo

SUMMARY: A week after transport a 4 month old buffalo calf developed diarrhoea. Its condition gradually deteriorated and it died. Necropsy revealed acute haemorrhagic enteritis and enlarged mesenteric lymph nodes. Haemorrhages and numerous microabscesses were detected in the lamina propria of the small intestine associated with colonies of Gram negative bacteria. Yersinia pseudotuberculosis was isolated from the small intestine and from mesenteric lymph node. Enteritis caused by Y pseudotuberculosis does not appear to have been reported previously in buffalo in Australia.     

Experimental toxoplasmosis in buffalo calves

Eight buffalo calves were inoculated with infectious oocysts of a virulent strain of Toxoplasma gondii, five with 1 × 10⁵, and the other three with 5 × 10⁵ oocysts each while two more were kept as non-inoculated controls. Infected animals developed pyrexia, anorexia, conjunctivitis and dyspnoea. The clinical symptoms, haematological changes and serological response were of a low order. The appearance of haemagglutinating antibodies at significant levels (? 1:64) was first observed at 21 days after inoculation (DAI), peaked at 42 DAI and rapidly declined after 63 DAI. The inoculated calves were killed (or died) at intervals from 11 DAI to 110 DAI. The organism could be recovered from several times of a calf that died 11 DAI, but was rapidly removed subsequently. Only the lymph nodes were infective till 32 DAI. Parasitism of the retina was demonstrated in one calf. The significance of these findings is discussed.     

Pharmacokinetics of a single intramuscular injection of cefquinome in buffalo calves

The objective of this study was to investigate the pharmacokinetics of cefquinome following single intramuscular (IM) administration in six healthy male buffalo calves. Cefquinome was administered intramuscularly (2 mg/kg bodyweight) and blood samples were collected prior to drug administration and up to 24 hr after injection. No adverse effects or changes were observed after the IM injection of cefquinome. Plasma concentrations of cefquinome were determined by high‐performance liquid chromatography. The disposition of plasma cefquinome is characterized by a mono‐compartmental open model. The pharmacokinetic parameters after IM administration (mean ± SE) were C_max 6.93 ± 0.58 μg/ml, T_max 0.5 hr, t_½kα 0.16 ± 0.05 hr, t_½β 3.73 ± 0.10 hr, and AUC 28.40 ± 1.30 μg hr/ml after IM administration. A dosage regimen of 2 mg/kg bodyweight at 24‐hr interval following IM injection of cefquinome would maintain the plasma levels required to be effective against the bacterial pathogens with MIC values ≤0.39 μg/ml. The suggested dosage regimen of cefquinome has to be validated in the disease models before recommending for clinical use in buffalo calves.